Literature DB >> 28359248

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

Cirino Botta1, Maria Cuce1, Daniele Caracciolo1, Lucia Fiorillo1, Pierosandro Tagliaferri1, Pierfrancesco Tassone1.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM cells and infiltrating immune cells, which have been reported to promote proliferation, survival and drug resistance of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules with regulatory functions in the cell, whose expression has predictive and prognostic value in different malignancies. MiRNAs are gaining increasing interest due to their capability to polarize the immune-response through different mechanisms, which include the molecular reprogramming of immune cells. This characteristic, together with the antitumor activity of miRNA mimics or inhibitors, make the miRNA network an attractive area of investigation for novel anti-MM therapeutic approaches. In this review, we will discuss the recent advances in the understanding of the interplay between MM cells and bone marrow resident immune cells, with special focus on the molecular and functional changes induced by miRNA network modulation. We will finally indicate potential targets for therapeutic intervention. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  MicroRNA; immune-response.; immunotherapy; miRNA; multiple myeloma; tumor immunology

Mesh:

Substances:

Year:  2017        PMID: 28359248     DOI: 10.2174/1568009617666170330154756

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  8 in total

1.  Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach.

Authors:  Chiara Bianca Maria Platania; Rosa Maisto; Maria Consiglia Trotta; Michele D'Amico; Settimio Rossi; Carlo Gesualdo; Giovanbattista D'Amico; Cornel Balta; Hildegard Herman; Anca Hermenean; Franca Ferraraccio; Iacopo Panarese; Filippo Drago; Claudio Bucolo
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

2.  In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection.

Authors:  Amirhossein Ahmadi; Sharif Moradi
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

3.  Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Authors:  Maria Cucè; Maria Eugenia Gallo Cantafio; Maria Anna Siciliano; Caterina Riillo; Daniele Caracciolo; Francesca Scionti; Nicoletta Staropoli; Valeria Zuccalà; Lorenza Maltese; Anna Di Vito; Katia Grillone; Vito Barbieri; Mariamena Arbitrio; Maria Teresa Di Martino; Marco Rossi; Nicola Amodio; Pierosandro Tagliaferri; Pierfrancesco Tassone; Cirino Botta
Journal:  J Hematol Oncol       Date:  2019-03-21       Impact factor: 17.388

4.  Tumor immune cell infiltration score based model predicts prognosis in multiple myeloma.

Authors:  Can Chen; Yiwei Li; Peiwen Miao; Ying Xu; Yaping Xie; Zhenzhen Chen; Shenxian Qian
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

Review 5.  Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.

Authors:  Cirino Botta; Francesco Mendicino; Enrica Antonia Martino; Ernesto Vigna; Domenica Ronchetti; Pierpaolo Correale; Fortunato Morabito; Antonino Neri; Massimo Gentile
Journal:  Cancers (Basel)       Date:  2021-06-28       Impact factor: 6.639

6.  Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.

Authors:  Cirino Botta; Rita Maria Agostino; Vincenzo Dattola; Vittoria Cianci; Natale Daniele Calandruccio; Giovanna Bianco; Antonino Mafodda; Roberto Maisano; Eleonora Iuliano; Giovanna Orizzonte; Domenico Mazzacuva; Antonia Consuelo Falzea; Rita Emilena Saladino; Rocco Giannicola; Giorgio Restifo; Umberto Aguglia; Michele Caraglia; Pierpaolo Correale
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

7.  MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Authors:  C Botta; M Cucè; M R Pitari; D Caracciolo; A Gullà; E Morelli; C Riillo; L Biamonte; M E Gallo Cantafio; R Prabhala; C Mignogna; A Di Vito; E Altomare; N Amodio; M T Di Martino; P Correale; M Rossi; A Giordano; N C Munshi; P Tagliaferri; P Tassone
Journal:  Leukemia       Date:  2017-11-21       Impact factor: 11.528

Review 8.  Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.

Authors:  Dan Chen; Xinhong Yang; Min Liu; Zhihua Zhang; Enhong Xing
Journal:  Cancer Gene Ther       Date:  2021-01-05       Impact factor: 5.987

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.